# Alzprotect

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/alzprotect

- Industry: Pharmaceuticals
- Headquarters: Loos, France
- Website: www.alzprotect.com
- Total disclosed funding: $4.2M
- Latest round: Series B (Jan 31, 2018)
- Investors on record: 4

## About

Alzprotect SAS is a biopharmaceutical company focused on developing innovative therapies for neurodegenerative diseases, particularly targeting tauopathies such as Alzheimer’s disease and Progressive Supranuclear Palsy (PSP).Founded in 2007, Alzprotect SAS is headquartered in Loos, France. The company specializes in creating therapeutic solutions for neurodegenerative diseases through innovative approaches. Patricia Melnyk founded the company, which has raised EUR 1.95 mn in its latest funding round from Xerys Gestion on January 25, 2024. Alzprotect has completed 12 deals to date, achieving a current valuation of EUR 68.921 mn. The company has not undergone any reported pivots or changes in operational strategy.Alzprotect specializes in developing therapeutic solutions for neurodegenerative diseases, focusing on tauopathies like PSP and Alzheimer’s disease. Their primary product, AZP2006, aims to halt neurodegeneration and restore brain functions by targeting markers associated with neurodegenerative diseases. They cater to healthcare providers and research institutions across Europe, North America, and Asia.Alzprotect generates revenue through partnerships and collaborations in the biopharmaceutical sector, particularly in clinical trials and research agreements. Collaborations with healthcare systems, research institutions, and pharmaceutical companies involve the exchange of proprietary technologies and products, like AZP2006, for funding and shared royalties. These collaborations may also include licensing agreements, enhancing the company's reach in the global healthcare landscape.Alzprotect SAS plans to leverage the recent EUR 1.95 mn funding to support the development and launch of new products, including AZP2006. The company aims to expand its market presence in Europe, North America, and Asia by establishing new partnerships and collaborations by the end of 2025. The funding will facilitate clinical trials and further research efforts, ensuring the timely delivery of innovative therapies to combat neurodegenerative diseases.

## Funding rounds

- Series B, Jan 31, 2018, $4.2M — Finovam Gestion, Nord France Amorcage, Xerys Gestion, Participations Besançon

## Investors

- Finovam Gestion (https://capitalatlas.ai/funds/finovam-gestion) — Series B
- Nord France Amorcage — Series B
- Xerys Gestion (https://capitalatlas.ai/funds/xerys-gestion) — Series B
- Participations Besançon — Series B